Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach.

J Transl Med · 2025 · PMC11727291 · PMID 39806405

Europe PMC DOI

hedged sentence

0.0056

closest p · 0.1× alpha

0.0056

boldest claim

The sentences

highly significantp = 0.0056actually significant

Furthermore, adding 10 μL of αB7-H3-αCD3 BITE supernatant into PHA-L-activated T cells at E:T ratio of 10:1 resulted in highly significant cytotoxicity against L-363 (B7-H3 medium ; Fig. 8 C) and KMS-12-PE (B7-H3 high ; Fig. 8 D) cells, with percentages of 55.0 ± 5.2% ( p = 0.0056), 32.7 ± 4.4%, and ( p = 0.0067) compared to the negative controls (33.4 ± 2.0%, and 6.7 ± 3.0%, respectively).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.